- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02626858
Optimizing the Delineation of the Tumour Bed in Breast Irradiation
December 7, 2015 updated by: Universitaire Ziekenhuizen KU Leuven
The aim of the present study is:
- to verify whether the delineation of the tumour bed, based on the combination of the visible postoperative changes and the position of the surgical clips on a CT scan in treatment position acquired 1 week before the start of the radiotherapy (RT), provides an accurate localisation of the boost volume compared to the localisation of the tumour on a pre-operative CT-scan.
- to document the changes that occur in the tumour bed as seen on a CT scan as a function of the delay between surgery and radiotherapy.
- to determine the ideal number and the positioning of the clips needed to reproduce the best treatment volume for the boost.
- to propose new guidelines for tumour bed definition and delineation based on the study findings.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Start of the study: february 2012
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leuven, Belgium, 3000
- UZ Leuven
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Breast Cancer patients, without metastases, who will undergo breast conserving surgery and probably will receive adjuvant chemotherapy and thereafter radiotherapy.
Exclusion Criteria:
- Metastases at time of diagnosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: extra treatment planning CT-scan
Extra pre-operative CT-scan for treatment planning in RT
|
Beside the standard post-operative CT-scan, an extra pre-operative CT-scan is performed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the interobserver variability (IOV) (%) of the delineated Clinical Target Volume (CTV) boost (cm3) with and without the fusion of the pre-operative CT-scan.
Time Frame: 2 years
|
2 years
|
|
the volume of the delineated CTVboost (cm3) with and without the fusion of the pre-operative CT-scan.
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the correlation of the Cavity Visibility Scale (CVS) to volume changes and IOV
Time Frame: 2 Years
|
2 Years
|
|
the volume changes over time (in case of adjuvant chemotherapy)
Time Frame: 2 years
|
2 years
|
|
the usefulness of the surgical clips assessed by the 6 observers.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Caroline Weltens, PhD, Universitaire Ziekenhuizen KU Leuven
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (Actual)
December 1, 2013
Study Completion (Actual)
July 1, 2015
Study Registration Dates
First Submitted
September 28, 2015
First Submitted That Met QC Criteria
December 7, 2015
First Posted (Estimate)
December 10, 2015
Study Record Updates
Last Update Posted (Estimate)
December 10, 2015
Last Update Submitted That Met QC Criteria
December 7, 2015
Last Verified
February 1, 2012
More Information
Terms related to this study
Other Study ID Numbers
- s54017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on extra treatment planning CT-scan
-
University of LouisvilleJames Graham Brown Cancer CenterActive, not recruitingLung CancerUnited States
-
HyperfusionUniversity Hospital, GhentUnknownMetastatic Lung Cancer | Cancer, Lung | Metastatic Liver Cancer | Cancer Liver | Perfusion Computed Tomography Target LesionBelgium
-
Royal Marsden NHS Foundation TrustInstitute of Cancer Research, United KingdomUnknown
-
Institut Cancerologie de l'OuestCompleted
-
AHS Cancer Control AlbertaCalgary Health RegionUnknownLung Neoplasms | Positron Emission TomographyCanada
-
Northwestern UniversityCompletedChronic RhinosinusitisUnited States
-
University of MiamiCompletedHead and Neck Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnMalignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm | Refractory Sclerodermatous Graft Versus Host DiseaseUnited States
-
Tianjin Medical University Cancer Institute and...Completedthe Diffenence of Different Detector Row 4DCT,Especially in Artifects,Radiation Dose and Target VolumeChina
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnSquamous Cell Carcinoma of Head and Neck